Additional limitations include the lack of matched/paired non-cancer tissue and the lack of germ-line testing to identify patients with Lynch syndrome as well as tumor heterogeneity, which can contribute to the variability of HER2 status across tumor types. This evidence concerns the gene ERBB2 and Lynch syndrome.